mazindol has been researched along with Parkinsonian Disorders in 6 studies
Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tel, BC | 1 |
| Zeng, BY | 1 |
| Cannizzaro, C | 1 |
| Pearce, RK | 2 |
| Rose, S | 1 |
| Jenner, P | 2 |
| Porritt, MJ | 1 |
| Batchelor, PE | 1 |
| Howells, DW | 1 |
| Pope-Coleman, A | 1 |
| Tinker, JP | 1 |
| Schneider, JS | 1 |
| Costa, S | 1 |
| Marsden, CD | 1 |
| Xu, K | 1 |
| Xu, YH | 1 |
| Chen, JF | 1 |
| Schwarzschild, MA | 1 |
| Breysse, N | 1 |
| Baunez, C | 1 |
| Spooren, W | 1 |
| Gasparini, F | 1 |
| Amalric, M | 1 |
6 other studies available for mazindol and Parkinsonian Disorders
| Article | Year |
|---|---|
Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dopamine Uptake Inhibitors; Dyskinesia, Dr | 2002 |
Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
Topics: Animals; Binding, Competitive; Brain-Derived Neurotrophic Factor; Cell Death; Cell Survival; Disease | 2005 |
Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Binding Sites; Dopamine Agents; | 2000 |
Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Callithrix | 1999 |
Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Caffeine; Dopamine; Dopamine A | 2002 |
Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism.
Topics: Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Excitatory Amino Acid Antagonists; Kinetics; | 2002 |